Acceder

Publicaciones - TRASPLANTE HEMATOPOYÉTICO / TERAPIA CELULAR

Cargando...
Gómez García LM, Escudero A, Mestre C, Fuster Soler JL, Martínez AP, Vagace Valero JM, Vela M, Ruz B, Navarro A, Fernández L, Fernández A, Leivas A, Martínez-López J, Ferreras C, De Paz R, Blanquer M, Galán V, González B, Corral D, Sisinni L, Mirones I, Balas A, Vicario JL, Valle P, Borobia AM, Pérez-Martínez A. Phase 2 Clinical Trial of Infusing Haploidentical K562-mb15-41BBL-Activated and Expanded Natural Killer Cells as Consolidation Therapy for Pediatric Acute Myeloblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2021 Jan 25. pii: S2152-2650(21)00021-5. doi: 10.1016/j.clml.2021.01.013. [Epub ahead of print] PubMed PMID: 33610500.
AÑO: 2021; IF: 2.298
Norte-Muñoz M, Lucas-Ruiz F, Gallego-Ortega A, García-Bernal D, Valiente-Soriano FJ, de la Villa P, Vidal-Sanz M, Agudo-Barriuso M. Neuroprotection and Axonal Regeneration Induced by Bone Marrow Mesenchymal Stromal Cells Depend on the Type of Transplant. Front Cell Dev Biol. 2021 Nov 4;9:772223. doi: 10.3389/fcell.2021.772223. eCollection 2021. PubMed PMID: 34805178; PubMed Central PMCID: PMC8600074.
AÑO: 2021; IF: 5.186
Melero-Amor A, Romecín P, Iyú D, García-Bernal D, García-Navaro E, Moraleda JM, García-Estañ J, García-Candel F, Atucha NM. Platelet function and microvesicle generation in patients with hemophilia A. Clin Case Rep. 2021 Jan 19;9(3):1408-1415. doi: 10.1002/ccr3.3788. eCollection 2021 Mar. PubMed PMID: 33768856; PubMed Central PMCID: PMC7981769.
AÑO: 2021
Richardson E, García-Bernal D, Calabretta E, Jara R, Palomo M, Baron RM, Yanik G, Fareed J, Vlodavsky I, Iacobelli M, Díaz-Ricart M, Richardson PG, Carlo-Stella C, Moraleda JM. Defibrotide: potential for treating endothelial dysfunction related to viral and post-infectious syndromes. Expert Opin Ther Targets. 2021 Jun 25:1-11. doi: 10.1080/14728222.2021.1944101. [Epub ahead of print] PubMed PMID: 34167431.
AÑO: 2021; IF: 5.473
Goicoechea I, Puig N, Cedena MT, Burgos L, Cordón L, Vidriales MB, Flores-Montero J, Gutierrez NC, Calasanz MJ, Ramos MM, Lara-Astiaso D, Vilas-Zornoza A, Alignani D, Rodriguez I, Sarvide S, Alameda D, Garcés JJ, Rodriguez S, Fresquet V, Celay J, Garcia-Sanz R, Martinez-Lopez J, Oriol A, Rios R, Martin-Sanchez J, Martinez-Martinez R, Sarra J, Hernandez MT, de la Rubia J, Krsnik I, Moraleda JM, Palomera L, Bargay J, Martinez-Climent JA, Orfao A, Rosiñol L, Mateos MV, Lahuerta JJ, Blade J, San Miguel J, Paiva B. Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma. Blood. 2021 Jan 7;137(1):49-60. doi: 10.1182/blood.2020006731. PubMed PMID: 32693406.
AÑO: 2021; IF: 17.794
Siguiente >

Instituto de Investigación Sanitaria Acreditado

ISCII